By Editor , 25 September 2026
GAC's Amorphous Motor Tech Wins Top Honor at Geneva Inventions Expo

Guangzhou – September 25, 2026 -- GAC Group's electric drive project has won the Gold Medal with the Congratulations of the Jury, the highest distinction at the 51st International Exhibition of Inventions Geneva, an award requiring unanimous jury approval selected from among all Gold Medal winners.

By Editor , 25 September 2026
Brightray Signs Framework for 40MW Modular AI Data Center in Macao

Singapore – September 25, 2026 -- Brightray Veridian Pte. Ltd., a wholly owned subsidiary of Brightray Science Inc., has signed a Prefabricated Module Sales Framework Agreement with a Macao-based developer for a planned 40MW artificial intelligence data center in Coloane, Macao, with delivery targeted for the third quarter of 2027.

By Editor , 25 September 2026
Fresenius Medical Care Exits China PD Business, Books €110M Charge

Bad Homburg, Germany – September 25, 2026 -- Fresenius Medical Care will exit its peritoneal dialysis business in China and discontinue local production and sales of its 4008A hemodialysis system, triggering one-time costs of approximately €110 million in the third quarter of 2026.

The charge, tied to impairment, scrappage and termination costs, will be treated as a special item and is not expected to meaningfully affect the future revenue outlook for the China business within the Company's Care Enablement segment.

By Editor , 25 September 2026

Shanghai – September 25, 2026 -- Nutshell Therapeutics (Shanghai) Co., Ltd. has received FDA clearance of its Investigational New Drug (IND) application for NTS231, a covalent allosteric molecular glue degrader targeting NRF2, allowing the company to begin clinical development in the United States. NTS231 is the first NRF2 degrader originating from China and only the second such molecule worldwide to reach clinical-stage development.

By Editor , 25 September 2026

Beijing – September 25, 2026 -- Yiren Digital Ltd. (NYSE: YRD) will release unaudited financial results for the second quarter ended June 30, 2026, before U.S. markets open on Wednesday, September 30, 2026.

By Editor , 25 September 2026
iQIYI Unveils 350+ Titles, AI Drama as Content Strategy Reboots

Beijing – September 25, 2026 -- iQIYI unveiled a slate of more than 350 new titles for 2026-2027 at its iJOY Conference held September 23 in Shanghai, anchoring the launch around a new "All in AI" production and marketing strategy. The Chinese streaming platform also confirmed that its flagship Scream Night event will run December 5 at Galaxy Arena in Macao under a renewed three-year residency agreement covering 2026 to 2028.

By Editor , 25 September 2026
Xi Pledges 100,000 US Youth Exchanges as China-US Trade Ties Deepen

Beijing -- Chinese President Xi Jinping announced on September 24, 2026 that China will invite 100,000 young Americans for exchange and study programs over the next five years, a pledge made during a White House welcome ceremony marking his state visit to the United States.

By Editor , 25 September 2026
XtalPi Files FDA IND for First Gut-Restricted Pan-TRK Pain Drug

Boston and Shenzhen – September 24, 2026 -- XtalPi Holdings Limited (HKEX: 2228) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for KQTD-126, a potential first-in-class gut-restricted pan-tropomyosin receptor kinase (pan-TRK) inhibitor targeting chronic intestinal pain in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).

By Editor , 25 September 2026

Quanzhou, China – September 24, 2026 -- INLIF LIMITED (Nasdaq: INLF) swung to a net income of $1.01 million in the first half of fiscal year 2026, reversing a $1.98 million net loss in the same period last year, an improvement of approximately $3.0 million.

By Editor , 25 September 2026

Shanghai – September 24, 2026 -- Sanyou Biopharmaceuticals Co., Ltd. and NovoCodex Biopharmaceuticals Co., Ltd. have signed a strategic collaboration agreement to jointly develop next-generation antibody-drug conjugates (ADCs), combining Sanyou Bio's AI-driven antibody discovery platforms with NovoCodex's clinically validated site-specific conjugation technology.